Key Points
- Major shareholder & Johnson Johnson sold 2,200 CVRx shares on Nov. 24 at $10.06 (≈$22,132), cutting their stake by 0.05% to 4,047,198 shares (~$40.7M); the sale follows several November disposals including 52,332 shares on Nov. 6.
- CVRx opened at $9.99 (50‑day MA $9.15, 200‑day MA $7.76) with a market cap of ~$261.8M and a 52‑week range of $4.30–$18.55; the company slightly beat Q3 EPS estimates (‑$0.49 vs. ‑$0.50) and carries a MarketBeat consensus of “Moderate Buy” with a $13.17 target.
CVRx, Inc. (NASDAQ:CVRX - Get Free Report) major shareholder & Johnson Johnson sold 2,200 shares of the company's stock in a transaction that occurred on Monday, November 24th. The stock was sold at an average price of $10.06, for a total value of $22,132.00. Following the transaction, the insider owned 4,047,198 shares of the company's stock, valued at approximately $40,714,811.88. This trade represents a 0.05% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Large shareholders that own at least 10% of a company's stock are required to disclose their transactions with the SEC.
& Johnson Johnson also recently made the following trade(s):
- On Friday, November 21st, & Johnson Johnson sold 500 shares of CVRx stock. The stock was sold at an average price of $10.00, for a total transaction of $5,000.00.
- On Wednesday, November 12th, & Johnson Johnson sold 1,000 shares of CVRx stock. The stock was sold at an average price of $10.00, for a total transaction of $10,000.00.
- On Friday, November 7th, & Johnson Johnson sold 200 shares of CVRx stock. The shares were sold at an average price of $10.00, for a total transaction of $2,000.00.
- On Thursday, November 6th, & Johnson Johnson sold 52,332 shares of CVRx stock. The shares were sold at an average price of $10.21, for a total transaction of $534,309.72.
CVRx Stock Performance
NASDAQ:CVRX opened at $9.99 on Wednesday. The firm's 50-day moving average is $9.15 and its 200-day moving average is $7.76. The company has a market cap of $261.84 million, a price-to-earnings ratio of -4.76 and a beta of 1.28. The company has a debt-to-equity ratio of 0.85, a quick ratio of 10.78 and a current ratio of 11.99. CVRx, Inc. has a 52-week low of $4.30 and a 52-week high of $18.55.
CVRx (NASDAQ:CVRX - Get Free Report) last released its earnings results on Wednesday, November 5th. The company reported ($0.49) earnings per share for the quarter, topping analysts' consensus estimates of ($0.50) by $0.01. CVRx had a negative return on equity of 79.31% and a negative net margin of 95.61%.The business had revenue of $14.69 million for the quarter, compared to the consensus estimate of $14.16 million. CVRx has set its Q4 2025 guidance at EPS. FY 2025 guidance at EPS. Equities research analysts anticipate that CVRx, Inc. will post -1.91 earnings per share for the current year.
Analyst Ratings Changes
A number of brokerages recently commented on CVRX. Weiss Ratings restated a "sell (e+)" rating on shares of CVRx in a research note on Thursday, October 30th. Cantor Fitzgerald increased their price objective on shares of CVRx from $11.00 to $13.00 and gave the company an "overweight" rating in a research note on Thursday, November 6th. Finally, Canaccord Genuity Group upped their target price on shares of CVRx from $9.00 to $11.00 and gave the company a "buy" rating in a research note on Thursday, November 6th. One investment analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and two have given a Sell rating to the company. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus target price of $13.17.
Get Our Latest Research Report on CVRX
Institutional Investors Weigh In On CVRx
Institutional investors and hedge funds have recently made changes to their positions in the company. AlphaQuest LLC increased its position in shares of CVRx by 114.6% during the 2nd quarter. AlphaQuest LLC now owns 13,106 shares of the company's stock worth $77,000 after purchasing an additional 6,998 shares in the last quarter. Corton Capital Inc. bought a new stake in CVRx during the second quarter worth about $176,000. Nuveen LLC acquired a new stake in shares of CVRx during the first quarter worth approximately $517,000. Russell Investments Group Ltd. raised its stake in shares of CVRx by 70.1% in the first quarter. Russell Investments Group Ltd. now owns 61,133 shares of the company's stock valued at $748,000 after acquiring an additional 25,194 shares during the last quarter. Finally, Parkman Healthcare Partners LLC boosted its holdings in shares of CVRx by 33.5% in the 1st quarter. Parkman Healthcare Partners LLC now owns 1,229,522 shares of the company's stock worth $15,037,000 after acquiring an additional 308,348 shares in the last quarter. Institutional investors and hedge funds own 75.27% of the company's stock.
About CVRx
(
Get Free Report)
CVRx, Inc, a commercial-stage medical device company, focuses on developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. The company offers Barostim, a neuromodulation device indicated to improve symptoms for patients with heart failure with reduced ejection fraction or systolic heart failure.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
